South African pharmaceutical group Adcock Ingram says its businesses in Zimbabwe and Kenya have continued to underperform, cumulatively incurring a trading loss of $69 000 in the six months to December, 2016.
The Johannesburg listed company has interests in flagging Bulawayo-based pharmaceutical manufacturer and distributor Datlabs, whose production capacity has been going down due to operational challenges.
“The units in Zimbabwe and Kenya have for some time underperformed in challenging markets. These entities fortunately constitute a very small percentage of Group assets and collectively incurred a trading loss of R0.9 million during the period under review,” the company said in its unaudited group interim results for the six months ended 31 December 2016.
Datlabs produces leading brands such as Cafemol, Panado, Solphyllex and Lanolene Milk under licence but has been facing serious competition from imports mainly from the Asian bloc.
The company has been seeking close to $10 million to recapatilise its operations.-The Source
(73 VIEWS)
Britain says amendment of the Zimbabwe constitution is a sovereign, legislative matter for Zimbabwe to…
It is now 47 years since I wrote the short story below for a South…
Zimbabwe has released its 2026 monetary policy statement in which it seeks to stabilise its…
Far from it, on paper that is. Ignatius Chombo was one of the longest serving…
Zimbabwe on Thursday announced a ZiG290.9 billion budget with revenue expected to be ZiG287.6 billion,…
The International Monetary Fund says Zimbabwe’s economic recovery in 2025 is stronger than previously anticipated…